Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium
NCT ID: NCT01288404
Last Updated: 2011-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2008-01-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
NCT02342392
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
NCT00593450
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
NCT00288561
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
NCT00058994
Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
NCT01217944
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Anti-VEGF therapy
* Bevacizumab
* Subconjunctival injection
* Suppress neovascularization
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
topical 0.1% fluorometholone eye drops
Fluorometholone
topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
Bevacizumab group 1
Bevacizumab 1.25 mg/0.05mL
Bevacizumab
subconjunctival bevacizumab 1.25 mg/0.05mL
Bevacizumab group 2
Bevacizumab 2.5 mg/0.1mL
Bevacizumab
subconjunctival bevacizumab 2.5 mg/0.1mL
bevacizumab group 3
bevacizumab 3.75 mg/0.15mL
Bevacizumab
subconjunctival bevacizumab 3.75 mg/0.15mL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluorometholone
topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
Bevacizumab
subconjunctival bevacizumab 1.25 mg/0.05mL
Bevacizumab
subconjunctival bevacizumab 2.5 mg/0.1mL
Bevacizumab
subconjunctival bevacizumab 3.75 mg/0.15mL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Failure of conventional topical anti-inflammatory therapy for impending recurrent pterygium which was defined by the progression of fibrovascular tissue over the excised area despite receiving treatment.
3. No history of any adjunctive treatment such as MMC, 5-FU, periocular injection of corticosteroids and beta radiation.
4. No other ocular surface pathologies or coexisting ocular diseases.
5. No other ocular surgeries within the previous 6 months.
6. No history of allergy to the medications used in this study.
7. Good compliance with the study regimen and availability for the duration of the entire study period.
Exclusion Criteria
2. Hypertension
3. Pregnant or lactating women
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ramathibodi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ramathibodi Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaevalin Lekhanont, MD
Role: PRINCIPAL_INVESTIGATOR
Ramathibodi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ramathibodi Hospital
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
055217
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.